[go: up one dir, main page]

BR0010704A - Composições e métodos de anti-náusea - Google Patents

Composições e métodos de anti-náusea

Info

Publication number
BR0010704A
BR0010704A BR0010704-2A BR0010704A BR0010704A BR 0010704 A BR0010704 A BR 0010704A BR 0010704 A BR0010704 A BR 0010704A BR 0010704 A BR0010704 A BR 0010704A
Authority
BR
Brazil
Prior art keywords
compositions
methods
nausea
nausea compositions
vomiting
Prior art date
Application number
BR0010704-2A
Other languages
English (en)
Inventor
Marc S Hermelin
Mitchell I Kirschner
R Saul Levinson
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23173252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010704(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of BR0010704A publication Critical patent/BR0010704A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES E MéTODOS DE ANTI-NáUSEA". A presente invenção é direcionada a novas composições de anti-náusea, composições anti-eméticas e métodos usando as mesmas para fornecer alívio de náusea e/ou vómito. As composições são particularmente úteis a mulheres grávidas.
BR0010704-2A 1999-05-03 2000-04-28 Composições e métodos de anti-náusea BR0010704A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/303,690 US6197329B1 (en) 1999-05-03 1999-05-03 Anti-nausea compositions and methods
PCT/US2000/011693 WO2000066082A1 (en) 1999-05-03 2000-04-28 Anti-nausea compositions and methods

Publications (1)

Publication Number Publication Date
BR0010704A true BR0010704A (pt) 2002-02-05

Family

ID=23173252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010704-2A BR0010704A (pt) 1999-05-03 2000-04-28 Composições e métodos de anti-náusea

Country Status (7)

Country Link
US (1) US6197329B1 (pt)
EP (1) EP1176948A4 (pt)
JP (1) JP2002543106A (pt)
AU (1) AU775868B2 (pt)
BR (1) BR0010704A (pt)
CA (1) CA2372225A1 (pt)
WO (1) WO2000066082A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156501A1 (en) * 2001-04-18 2002-10-24 Grey Thomas L. Method of relieving dizziness or vertigo
KR20030008446A (ko) * 2001-07-18 2003-01-29 정영내 생강을 주성분으로 하는 입덧완화 조성물
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US6887926B1 (en) 2001-11-16 2005-05-03 Oatey Co. Bonding compositions for chlorinated polymers and methods of using the same
WO2003092591A2 (en) * 2002-04-30 2003-11-13 Npd Llc Multi-phasic delivery via transmucosal absorption of antiemetic medicaments
AU2003239510A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
MXPA06000417A (es) * 2003-07-10 2006-03-17 Smithkline Beecham Corp Composiciones farmaceuticas.
JP4721631B2 (ja) * 2003-09-30 2011-07-13 小林製薬株式会社 催眠剤組成物
AT504041A1 (de) * 2003-11-04 2008-02-15 Szeles Josef Constantin Dr Verwendung von den enzymatischen abbau von endogenen opioid-neuropeptiden hemmenden substanzen
US20080213395A1 (en) * 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) * 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) * 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) * 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7585527B2 (en) * 2005-09-19 2009-09-08 Bala Venkataraman Composition and method for treating iron deficiency anemia
WO2007085888A1 (en) * 2006-01-27 2007-08-02 Wockhardt Limited Controlled release formulations of methylcobalamin
US20080248136A1 (en) * 2006-10-25 2008-10-09 Iomedix Development International Srl Acute and chronic heartburn composition and method
WO2008098195A2 (en) * 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
US20090004254A1 (en) * 2007-06-19 2009-01-01 Todd Maibach Film comprising active drugs
US9125844B1 (en) 2007-09-25 2015-09-08 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US7964189B1 (en) 2007-09-25 2011-06-21 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
WO2009118726A2 (en) * 2008-03-25 2009-10-01 Pregnant Princess & Co. Ltd. Oral combination of vitamins
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
US20110195130A1 (en) * 2010-02-09 2011-08-11 Sanford Siegal Edible compositions
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
CN104136004B (zh) 2012-02-22 2018-03-06 达切斯内公司 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
FR2995187B1 (fr) * 2012-09-10 2014-09-26 France Bebe Nutrition Lab Composition nutritionnelle pour femme enceinte
US20150024070A1 (en) * 2013-07-18 2015-01-22 Plato Chun-Chih Lee Ingestible canker sore treatment
PT3024466T (pt) * 2013-07-22 2018-07-13 Duchesnay Inc Composição para a gestão de náuseas e vómitos
US9452181B2 (en) * 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
BR112016026073B1 (pt) 2014-05-21 2021-11-03 Société des Produits Nestlé S.A. Processo para produção de uma composição nutricional impressa compreendendo pelo menos um nutriente, e sistema adaptado para sua execução
TWI595874B (zh) 2014-08-29 2017-08-21 達契斯奈股份有限公司 多西拉敏及吡哆醇及／或其代謝產物或鹽之多模式釋放調配物
CN104524301A (zh) * 2015-01-09 2015-04-22 杨茹芹 一种治疗痰浊阻胃型反胃病的中药
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
KR20190005199A (ko) 2016-05-05 2019-01-15 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
WO2018187767A1 (en) * 2017-04-06 2018-10-11 The Regents Of The University Of California Predicting, diagnosing, and treating nausea and vomiting of pregnancy
US20200113856A1 (en) * 2018-10-16 2020-04-16 Spencer B. Jones Non-prescription motion sickness medication containing an analgesic, an h2 blocker, and at least one antacid
AU2019428070B2 (en) * 2019-02-07 2025-09-11 The General Hospital Corporation Carotenoids for treating or preventing nausea
US11000540B1 (en) * 2019-11-22 2021-05-11 Al Siamon Treatment for reducing adverse events including chemotherapy discomfort and other conditions
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4634180A1 (en) 2022-12-15 2025-10-22 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025006921A1 (en) 2023-06-30 2025-01-02 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3073745A (en) * 1961-05-08 1963-01-15 White Lab Inc Anti-nausea compositions
AU526503B2 (en) * 1978-12-11 1983-01-13 Enzacor Properties Limited Electrolyte drink concentrate
US4309405A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4806354A (en) 1984-04-06 1989-02-21 Green James P Health food composition
US4738856A (en) 1985-05-13 1988-04-19 Nutrition Technologies, Inc. Beverage and method for making a beverage for the nutritional supplementation of calcium in humans
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
HU197510B (en) 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4994283A (en) 1987-07-02 1991-02-19 The Procter & Gamble Company Iron-calcium mineral supplements with enhanced bioavailability
DE4022944A1 (de) 1990-07-19 1992-01-23 Merck Patent Gmbh Sucralfat-kautablette
JP2002514170A (ja) * 1996-07-30 2002-05-14 エナージェティクス，インコーポレイティド 食品補充物
US5807586A (en) 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation

Also Published As

Publication number Publication date
AU4977900A (en) 2000-11-17
AU775868B2 (en) 2004-08-19
CA2372225A1 (en) 2000-11-09
US6197329B1 (en) 2001-03-06
EP1176948A1 (en) 2002-02-06
WO2000066082A1 (en) 2000-11-09
EP1176948A4 (en) 2007-06-20
JP2002543106A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
BR0010704A (pt) Composições e métodos de anti-náusea
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
DK1200418T3 (da) Nematodicide trifluorbutener
TR200102800T2 (tr) Yeni bileşikler.
MXPA03008714A (es) Polimeros secuenciados y composiciones cosmeticas que comprenden tales polimeros.
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
DK1144474T3 (da) Vandig reaktiv spartelmasse
BG103485A (en) Ketobanzamides as calpain inhibitors
PA8481301A1 (es) Derivados de 4,4-biarilpiperidina
DK1157037T3 (da) GCSF-konjugater
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
ATE285222T1 (de) Antiperspirant-zusammensetzungen
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL114294A0 (en) Sterol derivatives
MA24643A1 (fr) Tetrahydro-naphtalenes substitues et composes analogues
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
SE9802208D0 (sv) Novel compounds
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
CA2362698A1 (en) Resorcinol derivatives
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
CA2356985A1 (en) 5ht1 antagonists for antidepressant therapy
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/08, A61K 9/10, A61K 9/14, A61K 9/20, A61K 9/22, A61K 9/24, A61K 9/26, A61K 9/46, A61K 9/48, A61K 9/50, A61K 9/52

Ipc: A61K 31/4415 (2010.01), A61K 31/505 (2010.01), A61

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.